Some links on this page are affiliate links: if you buy through them we may earn a commission, at no extra cost to you.
Pfizer completed its purchase of Australian digital-health company ResApp Health in September 2022 for about A$180 million—roughly US$116–120 million at the time. ResApp had developed a smartphone-based cough-analysis algorithm intended to screen for COVID-19, but its early results were preliminary, and a later confirmatory-data condition in the acquisition agreement was not met. Pfizer bought the company and its broader respiratory technology, not a proven consumer app that could replace a PCR or rapid-antigen test.
What the cough technology was designed to do
ResApp’s software analyzed cough audio recorded on a smartphone, using machine learning to look for patterns associated with respiratory illness. Its COVID-19 algorithm was presented as a screening or triage tool: it could potentially help flag people for follow-up testing, but it was not established as a definitive diagnosis based on any cough, in any setting.
That distinction matters. A screening result is not the same as medical confirmation. ResApp described the COVID tool as a way to screen before a rapid antigen test or PCR test; a positive or uncertain result would still call for a recognized test. The company’s announcement of its early study reported results for 741 participants, including 446 who tested positive for COVID-19: 92% sensitivity and 80% specificity (ResApp’s study announcement).
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallWhat 92% sensitivity and 80% specificity mean
Sensitivity is the share of people who truly have the disease whom a test identifies as positive. At 92% sensitivity, the reported study results imply that some infected participants were missed. Specificity is the share of people who do not have the disease whom a test correctly identifies as negative. At 80% specificity, some people without COVID-19 would be incorrectly flagged.
#1 Best Overall
- FDA Authorized 15-Minute Self-Test: The test is a 15-minute self-test to detect whether or not an individual has COVID-19. The test can be completed in the comfort of your own home without the need to ship your sample to a lab.
- Easy to Use with Zero Discomfort: Test can be done by inserting 1/2 to 3/4 inch of a simple non-invasive nasal swab. Step-by-step instructional videos are available in our app (Installation of app is optional).
- For Ages 2 and Above : The self-administered test is recommended for individuals aged 15 years and older. Adult-collection is required for testing children 2-14 years old.
- Manage Group Testing Via Mobile App: The iHealth Test app allows the administrator of a small group to monitor and track the group members’ test results as needed at school, work or an event.
- Independently-sealed packaging ensures safe and hygienic testing. The swabs and test cards of iHealth COVID-19 Antigen Rapid Test are sealed and independently packaged to ensure the safety and hygiene of the product.
These figures are not an overall “accuracy” score, nor do they tell an individual the likelihood that a result is correct. That likelihood also depends on how common COVID-19 is in the group being screened. Results from an exploratory cohort do not automatically carry over to other populations, devices, recording conditions, variants, vaccination patterns, or people with different symptoms. Many respiratory conditions can affect cough sounds; the reported figures alone do not establish a unique cough signature for COVID-19.
How the acquisition price changed
The figures reported during the deal refer to different stages and currencies. The initial proposal was about A$100 million; the completed transaction was worth about A$180 million in Australian dollars. The familiar “nearly $120 million” headline is a rounded conversion into U.S. dollars, not the initial offer.
Rank #2
- COVID TEST KITS: 4 BinaxNOW COVID-19 Rapid Test Kits includes 4 foam-tipped swabs, 4 test cards, and 4 dropper bottles with simple instructions
- HSA/FSA ELIGIBLE: Abbott’s BinaxNOW at-home COVID test kits are HSA/FSA eligible
- TRUSTED TECHNOLOGY: FDA authorized BinaxNOW COVID tests utilize the same technology doctors use to test for COVID-19; BinaxNOW rapid COVID tests detect multiple COVID-19 variants*
- FAST COVID-19 TEST RESULTS: Each COVID rapid test provides fast, reliable results in just 15 minutes—no appointment required
- FOR AGES 2 and ABOVE: COVID-19 tests are suitable for kids when administered by an adult; ages 15 and older are able to self-administer COVID home tests with easy-to-follow instructions
| Stage | Offer or event |
|---|---|
| April 2022 | Pfizer proposed about A$100 million, or A$0.115 per ResApp share. |
| June 2022 | A revised scheme set A$0.146 per share, with A$0.207 per share conditional on specified confirmatory data performance and independent statistical confirmation. |
| June 2022 | The confirmatory-data condition was not satisfied, so the higher conditional amount did not apply under that structure. |
| August 2022 | Pfizer raised its best-and-final offer to A$0.208 per share. |
| September 2022 | The scheme was implemented at approximately A$180 million in equity value, often expressed in U.S. coverage as roughly US$116–120 million. |
The initial offer and final price are both accurate descriptions of the transaction at different points. The deal terms and subsequent offer are set out in ResApp’s revised scheme announcement and annual report; contemporary coverage also described the initial A$100 million proposal and the completed acquisition.
Why the confirmatory condition changes the story
The revised agreement tied the higher conditional payment to a follow-up data readout close to the March 2022 results: sensitivity could be no more than six percentage points below 92%, specificity no more than nine points below 80%, and a statistician had to confirm the results independently. The condition was not met. The available transaction material does not support substituting a precise final sensitivity-and-specificity pair for those original study results.
Rank #3
- Comprehensive 3-in-1 Test: The INDICAID COVID-flu test combo is a convenient way to detect COVID-19, Flu A, and Flu B. Everything you need is in this test home kit. It’s a must-have over-the-counter solution for anyone experiencing cold and flu symptoms.
- Fast, Reliable Results: This rapid influenza and COVID home test kit gives you 3 results in just 10 minutes, and it’s incredibly easy to use. All it requires is a shallow nasal swab, and the test can be completed in four simple steps. No more guessing!
- Trusted Technology: This flu and COVID test kit at home is FDA 510(k)-cleared, ensuring high-quality and accurate results. The combo test uses the same technology as COVID-19 rapid tests and can detect multiple COVID-19 and Flu A&B variants and strains.
- Versatile Use: The INDICAID COVID and flu test kit comes in a compact package, perfect for travel, school, work, and home. It’s also family-friendly. Individuals ages 14 and over can self-check, while children ages 2-14 require adult assistance.
- Extended Shelf Life: The shelf life of the INDICAID COVID-19/Flu A and Flu B Rapid Antigen Test has been extended to 16 months and is regularly extending. Simply scan the QR code on the box to find out the tests’ expiry date. Made in the USA.
Pfizer later raised its offer to A$0.208 per share anyway, and the acquisition proceeded. That sequence is important: the final purchase does not show that the cough algorithm reproduced its early performance or that Pfizer validated it as a clinical diagnostic.
Pfizer acquired a company, not just a COVID app
ResApp was a Brisbane-based company whose broader respiratory-disease technology grew out of research associated with the University of Queensland and was licensed to ResApp through UniQuest in 2014. The platform used cough and breathing sounds, alongside simple symptoms, to help identify respiratory conditions. ResApp’s work extended beyond COVID-19 to conditions including pneumonia, asthma, bronchitis, and chronic obstructive pulmonary disease. The University of Queensland described the technology and acquisition in its account of the deal.
Rank #4
- Fast Results in 10 Minutes – Get reliable Covid-19 test results in as little as 10 minutes, perfect for quick checks before gatherings or travel.
- Easy to Use, No Lab Needed – Simple step-by-step instructions allow you to self-administer the test at home with no need for professional assistance.
- Detects All Major Variants – Effectively identifies all known Covid-19 variants, giving you confidence in the test’s ability to track evolving strains.
- Compact and Travel-Friendly – Conveniently sized for travel, this kit allows you to test anywhere, giving you the flexibility to stay safe on the go.
- Only 5 turns per nostril —why bother with 10? Get quick and reliable results with less effort, making testing easier for the whole family, Our Covid-19 test kit for home works for individuals ages 2+.
Pfizer Australia Holdings Pty Limited, a wholly owned Pfizer subsidiary, acquired all of ResApp’s issued capital through a scheme of arrangement. The COVID screening algorithm was the headline-grabbing part, but the transaction concerned a broader respiratory platform and associated technology and capabilities.
Was the COVID algorithm approved or widely available?
The reviewed transaction and company materials do not establish that the COVID cough-screening feature became a widely available consumer app after Pfizer bought ResApp. Nor do they establish that it was FDA-authorized or cleared as a COVID diagnostic. ResApp’s FDA 510(k) clearance for SleepCheckRx in 2022 concerned a different product; it should not be treated as regulatory approval for the COVID algorithm. ResApp was removed from the Australian Securities Exchange official list after the acquisition was implemented (ASX announcement index).
Best Value
- #1 COVID-19 SELF TEST IN THE USA: Made with the same reliable technology used by doctors. Detects multiple COVID-19 variants, including Delta and Omicron*
- FAST RESULTS: At home test with results for you or your family in 15 minutes; no need for a prescription or sending to a lab
- TRUSTED TECHNOLOGY: Identical to the test used by professionals; intended for personal use with self-reported results and has Emergency Use Authorization from the FDA
- CONVENIENTLY TEST AT HOME: 2 nasal swab tests are included to detect active infection, with or without symptoms
- FSA/HSA ELIGIBLE: Test may be reimbursed, depending on coverage; contact your health insurance company to learn more
For readers checking the headline, the accurate short version is: Pfizer bought ResApp for about A$180 million, equivalent to roughly US$116–120 million at the time. ResApp’s experimental smartphone cough algorithm showed promising early screening results, but the later deal-related confirmatory condition was not satisfied. That is a very different claim from saying Pfizer purchased a finished app proven to diagnose COVID from a cough.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
